4th Annual CRISPR 2.0 2023

The 4th Annual CRISPR 2.0 Congress will represent the next frontier in the cell and gene therapy landscape. This event will showcase the latest and greatest CRISPR tools that are being developed and applied in therapeutic areas to translate to safer, more precise, and more efficient gene editing therapeutics into and throughout clinics.

The CRISPR 2.0 Summit will include over 30 speakers, 17 new data readouts, and 16 new tech pieces along with over 7 hours of networking across 3 conference days. The leading tracks of content the event will cover are Technology Innovation as well as Translating to the clinic. This will be accompanied by in-depth sessions on next-generation developments and therapeutic applications of CRISPR technologies, innovative in vivo and ex vivo CRISPR delivery approaches, and overcoming key translational limitations facing drug developers seeking to enter the clinic.

Prior to the conference days, there will be pre-conference workshop opportunities which are available to attend such as unpicking the Complexities of Intellectual Property (IP) Protection and Patent Disputes and First-in-Human CRISPR Trials where you can discover and understand new research, challenges, and various requirements within this field.

Industry-leading experts attending include Adebayo Lawal, Vice President, Head of Clinal Development from Editas Medicine, Christog Fellman, Head of CRISPR-X at CRISPR Therapeutics, and Priya Chockalingam, Vice President, Head of Clinical Bioanalytics and Translational Sciences from Beam Therapeutics, to name a few. Along with partners such as ThermoFisher Scientific, Aldevron, and Akron Bio who will be joining us there.

If your role is related to the gene and cell therapy field, this is a must-attend event to help capitalize on successes and challenges within this industry to push discussions and further advances more efficiently and effectively.

URLs:
Brochure: https://go.evvnt.com/1908815-0?pid=2874
Sponsor: https://go.evvnt.com/1908815-3?pid=2874
Website: https://go.evvnt.com/1908815-4?pid=2874

Category: Conferences | Science, Health and Medicine

Prices:
Drug Developer Pricing - Conference Only : USD 2999.00,
Drug Developer Pricing - Conference + Workshop OR Focus Day : USD 4297.00,
Academic Pricing - Conference Only : USD 2599.00,
Academic Pricing - Conference + Workshop OR Focus Day: USD 3697.00,
Vendor Pricing - Conference Only : USD 3799.00,
Vendor Pricing - Conference : USD 5297.00

Speakers: Adebayo Lawal - Vice President, Head of Clinal Development - Editas Medicine , Christof Fellmann - Head of CRISPR-X - CRISPR Therapeutics, Priya Chockalingam - Vice President, Head of Clinical Bioanalytics and Translational Sciences - Beam Therapeutics, Ryan Leenay - Associate Vice President - Gene Editing Eli Lilly, Socorro Portella - Vice President, Clinical Development - Caribou Biosciences, TJ Cradick - Chief Scientific Officer - Excision BioTherapeutics, Alan Brooks - Senior Vice President - Metagenomi, Andrew Anzalone - Director, Head of Prime Editing Platform - Prime Medicine, Andrew Torrance - Distinguished Professor of Law - University of Kansas School of Law, Ashley Hammad - Director of Clinical Research - Caribou Biosciences, Benjamin Haley - Professor - University of Montreal, Christopher Brown - Vice President of Discovery - Metagaenomi, Cian Schmitt-Ulms - Graduate Student, AbuGoot Lab - MIT, Cicera Lazzarotto - Senior Scientist - Beam Therapeutics, Connor Tsuchida - Graduate Student, Doudna Lab - UC Berkeley, Daniel Hart - Head of Technology Development - Epic Bio, Emily Pomeroy - Senior Scientist - Prime Medicine, Enrique Zudaire - Senior Vice President, Translational Sciences and Therapeutics Discovery - Caribou Biosciences, Eugenio Marco - Director - Editas Medicine, Gregory Newby - Assistant Professor - Johns Hopkins University, Jing Liao - Director, Vector Development and Operations - Alexion Pharmaceuticals, Joseph Nabhan - Chief Scientific Officer - Vesigen Therapeutics, Jungjoon Lee - Research Head, Platform Development Team - ToolGen, Laura Serwer - Senior Director, Head of Pharmacology and Toxicology - CRISPR Therapeutics, Mandana Arbab - Assistant Professor - Boston Children’s Hospital and Harvard Medical School, Omid Harandi - Vice President, Head of Cell Therapy - SalioGen, Qiyu Wang - Director - Vesigen Therapeutics, Rammohan Devulapally - Director, Nonviral Delivery - LifeEdit, Ross Wilson - Adjunct Assistant Professor - Wilson Lab, University of California at Berkeley, Sarah Denny - Director, Molecular Engineering - Scribe Therapeutics, Sourav Choudhury - Head of AAV Technologies - Sanofi, Speaker TBC - Aldevron, Speaker TBC - ThermoFIsher Scientific, Steven Wolk - Vice President, Chemistry and Boulder Site Head - Editas Medicine, Tamar Auerbach-Nevo - Vice President of Development - Emendo Biotherapeutics, Veronica Gough - Technology Innovation Scientist - Tune Therapeutics